Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). METHODS: In CREDENCE (Canaglifl...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahaffey, Kenneth W., Jardine, Meg J., Bompoint, Severine, Cannon, Christopher P., Neal, Bruce, Heerspink, Hiddo J.L., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Capuano, George, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Sun, Tao, Wheeler, David C., Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Brenner, Barry M., Perkovic, Vlado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727954/
https://www.ncbi.nlm.nih.gov/pubmed/31291786
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727954/
https://www.ncbi.nlm.nih.gov/pubmed/31291786
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007

Ejemplares similares